Nuvectra Corporation announced it has submitted supplementary chemical composition and biocompatibility data to the U.S. Food and Drug Administration (FDA) in support of the Company’s Virtis pre-market approval (PMA) application for the treatment of chronic urinary retention and symptoms of overactive bladder.